Yale Ventures


The university technology transfer office that manages disclosure assessment, intellectual property protection, licensing and contract negotiation, translational funding and accelerators, mentorship and investor engagement, commercialization training, and access coordination for institutional research infrastructure. The office supports formation of startups, negotiates agreements for material and sponsored research transfers, and maintains curated educational resources for faculty and researchers engaged in commercialization.

Industries

venture-capital-b37d

Nr. of Employees

small (1-50)

Yale Ventures

New Haven, Connecticut, United States, North America


Services

Assessment of disclosures, IP protection, marketing to industry, and negotiation of license and research agreements.

Review of novelty, patentability, market potential and development requirements for submitted invention disclosures; determination of appropriate protection strategy.

Selection and oversight of external patent counsel, drafting support, and management of prosecution activities including provisional and international filings.

Drafting and negotiation of MTAs, NDAs, option clauses, sponsored research and collaboration agreements with for‑profit entities and other institutions.

Milestone‑based grants and cohort programs to advance early translational projects, with mentorship and investor exposure.

Workshops, customer‑discovery training, playbooks and curated resources for stages from idea to fundraising.

View All Services

Expertise Areas

  • Technology transfer and commercialization
  • Invention disclosure assessment and IP strategy
  • Patent filing and prosecution management
  • Licensing agreements and contract negotiation
  • Show More (6)

Key Technologies

  • Digital health platforms
  • AI / machine learning modeling
  • Diagnostics development
  • Biologics and therapeutic development
  • Show More (2)

News & Updates

A university spinout entered a definitive agreement to be acquired for $3.05 billion; the spinout had advanced a therapeutic candidate into Phase 1/2 clinical data.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.